These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33679331)

  • 1. Indoleamine-2,3-Dioxygenase 1 Deficiency Suppresses Seizures in Epilepsy.
    Deng N; Hu J; Hong Y; Ding Y; Xiong Y; Wu Z; Xie W
    Front Cell Neurosci; 2021; 15():638854. PubMed ID: 33679331
    [No Abstract]   [Full Text] [Related]  

  • 2. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
    Yan EB; Frugier T; Lim CK; Heng B; Sundaram G; Tan M; Rosenfeld JV; Walker DW; Guillemin GJ; Morganti-Kossmann MC
    J Neuroinflammation; 2015 May; 12():110. PubMed ID: 26025142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of brain indoleamine 2,3-dioxygenase contributes to epilepsy-associated depressive-like behavior in rats with chronic temporal lobe epilepsy.
    Xie W; Cai L; Yu Y; Gao L; Xiao L; He Q; Ren Z; Liu Y
    J Neuroinflammation; 2014 Mar; 11():41. PubMed ID: 24594021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indoleamine 2,3-dioxygenase 1 deletion promotes Theiler's virus-induced seizures in C57BL/6J mice.
    Juda MB; Brooks AK; Towers AE; Freund GG; McCusker RH; Steelman AJ
    Epilepsia; 2019 Apr; 60(4):626-635. PubMed ID: 30770561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galectin 3 protects from cisplatin-induced acute kidney injury by promoting TLR-2-dependent activation of IDO1/Kynurenine pathway in renal DCs.
    Volarevic V; Markovic BS; Jankovic MG; Djokovic B; Jovicic N; Harrell CR; Fellabaum C; Djonov V; Arsenijevic N; Lukic ML
    Theranostics; 2019; 9(20):5976-6001. PubMed ID: 31534532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of indoleamine-2,3-dioxygenase 1, tryptophan-2,3-dioxygenase, and Ido1/Tdo2 knockout mice.
    Aslamkhan AG; Xu Q; Loughlin A; Vu H; Pacchione S; Bhatt B; Garfinkel I; Styring TG; LaFranco-Scheuch L; Pearson K; Reynolds S; Li N; Zhou H; Miller JR; Solban N; Bass A; Glaab WE
    Toxicol Appl Pharmacol; 2020 Nov; 406():115216. PubMed ID: 32871117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain.
    Mazarei G; Budac DP; Lu G; Lee H; Möller T; Leavitt BR
    Exp Neurol; 2013 Nov; 249():144-8. PubMed ID: 23994717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indoleamine 2,3-Dioxygenase 1 Deletion-Mediated Kynurenine Insufficiency Inhibits Pathological Cardiac Hypertrophy.
    Wang Y; Song J; Yu K; Nie D; Zhao C; Jiao L; Wang Z; Zhou L; Wang F; Yu Q; Zhang S; Wen Z; Wu J; Wang CY; Wang DW; Cheng J; Zhao C
    Hypertension; 2023 Oct; 80(10):2099-2111. PubMed ID: 37485661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.
    Doolin K; Allers KA; Pleiner S; Liesener A; Farrell C; Tozzi L; O'Hanlon E; Roddy D; Frodl T; Harkin A; O'Keane V
    Psychoneuroendocrinology; 2018 Sep; 95():8-17. PubMed ID: 29787958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of indoleamine 2,3-dioxygenase activity accelerates skin wound healing.
    Ito H; Ando T; Ogiso H; Arioka Y; Saito K; Seishima M
    Biomaterials; 2015 Jun; 53():221-8. PubMed ID: 25890721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of indoleamine 2,3-dioxygenase 1 (IDO1) and kynurenine pathway in the regulation of the aging process.
    Salminen A
    Ageing Res Rev; 2022 Mar; 75():101573. PubMed ID: 35085834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
    Heyes MP; Saito K; Major EO; Milstien S; Markey SP; Vickers JH
    Brain; 1993 Dec; 116 ( Pt 6)():1425-50. PubMed ID: 8293279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A peripheral blood mononuclear cell-based in vitro model: A tool to explore indoleamine 2, 3-dioxygenase-1 (IDO1).
    Gonçalves M; Furgiuele A; Rasini E; Legnaro M; Ferrari M; Luini A; Rodrigues-Santos P; Caramelo F; Marino F; Pereira FC; Cosentino M
    Eur J Pharmacol; 2024 Apr; 968():176420. PubMed ID: 38367683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDO1 Deficiency Does Not Affect Disease in Mouse Models of Systemic Juvenile Idiopathic Arthritis and Secondary Hemophagocytic Lymphohistiocytosis.
    Put K; Brisse E; Avau A; Imbrechts M; Mitera T; Janssens R; Proost P; Fallarino F; Wouters CH; Matthys P
    PLoS One; 2016; 11(2):e0150075. PubMed ID: 26914138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated serum levels of kynurenine pathway metabolites in patients with Behçet disease.
    Eryavuz Onmaz D; Tezcan D; Abusoglu S; Sivrikaya A; Kuzu M; Yerlikaya FH; Yilmaz S; Unlu A
    Amino Acids; 2022 Jun; 54(6):877-887. PubMed ID: 35604497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy.
    Wu L; Wang D; Chen Y; Qian M; Xu X; Zhang T; Bi N; Wang L
    Front Immunol; 2022; 13():906815. PubMed ID: 36032151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model.
    Poncelet L; Ait-Belkacem R; Marillier R; Gomes B; Stauber J
    J Pharm Biomed Anal; 2019 Jun; 170():220-227. PubMed ID: 30933897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms.
    Aeinehband S; Brenner P; Ståhl S; Bhat M; Fidock MD; Khademi M; Olsson T; Engberg G; Jokinen J; Erhardt S; Piehl F
    Brain Behav Immun; 2016 Jan; 51():47-55. PubMed ID: 26189678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indoleamine 2,3-dioxygenase 1 deficiency attenuates CCl4-induced fibrosis through Th17 cells down-regulation and tryptophan 2,3-dioxygenase compensation.
    Zhong W; Gao L; Zhou Z; Lin H; Chen C; Huang P; Huang W; Zhou C; Huang S; Nie L; Liu Y; Chen Y; Zhou D; Lv Z
    Oncotarget; 2017 Jun; 8(25):40486-40500. PubMed ID: 28465467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.
    Schefold JC; Zeden JP; Fotopoulou C; von Haehling S; Pschowski R; Hasper D; Volk HD; Schuett C; Reinke P
    Nephrol Dial Transplant; 2009 Jun; 24(6):1901-8. PubMed ID: 19155537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.